Article
Sofosbuvir-velpatasvir in Mexican patients with hepatitis C: A retrospective review.
Revista de gastroenterologia de Mexico (English) - 1 Jan 2000
Pérez-Hernández J L, Arce-Salinas C A, Lehmann-Mendoza R, Torre-Delgadillo A, Castro-Narro G E, Cerda-Reyes E, Ramos-Gómez M V, Juárez-Chavez L, Dehesa-Violante M, Muñoz-Espinoza L E, Cisneros-Garza L E, Aiza-Haddad I, Velarde-Ruiz-Velasco J A, Contreras-Omaña R, García-Casarreal N, Carmona-Castañeda A, Higuera-De la Tijera F
Abstract excerpt
INTRODUCTION: The sofosbuvir-velpatasvir (SOF/VEL) combination is a direct-acting antiviral therapy that is authorized and available in Mexico, making the performance of a real-world multicenter study that evaluates the sustained virologic response at 12 weeks post-treatment a relevant undertaking. METHODS: A retrospective review of the case records of 241 patients seen at 20 hospitals in Mexico was conducted to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.